Fortis Healthcare earnings calls.

Fortis Healthcare delivered a steady Q1 FY27 with consolidated revenue of INR 2,545Current reported value: 2,545. No comparable prior figure is available in the source record. crore (+17.5Current 17.5 crore vs previous available quarter 16.6 crore.% YoY), driven by robust hospital segment growth of 19% to INR 2,187 crore. EBITDA margin contracted 30bps YoY to 22.3% due to new facility ramp-up costs and one-time legal expenses, though management reiterated its FY28 target of 25% EBITDA margin. Hospital occupancy remained stable at 69% with occupied beds growing 17% to 3,418Current 3,418. Reported change: +17% YoY., while ARPO increased 2.6% to INR 2.71Current 2.71. Reported change: +2.6% YoY. lakh. Key specialties like renal sciences (+28%), neurosciences (+27%), and orthopedics (+23%) drove outperformance. The newly launched ESOP scheme ( INR 40 crore quarterly charge) aims to align doctor incentives and reduce attrition, with management confident this will offset costs through improved operational efficiency. Diagnostics business showed 10.2% growth with margin expansion to 23.9%. Management guided for 400 additional operational beds in remaining quarters and a proton therapy facility at Gurugram ( INR 250+ crore capex). Oncology growth moderation to ~10-12%Current reported value: Oncology growth moderation to ~10-12%. No comparable prior figure is available in the source record. from 27% due to CGHS/ECHS chemotherapy pricing changes remains a key monitorable. The 25% margin guidance by FY28 appears achievable if new facilities scale as expected, though Glen Eagles stabilization may take another 2-4Current reported value: 4. No comparable prior figure is available in the source record. quarters.